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Abstract
Background: Androgen deprivation therapy (ADT) is accompanied by a number of adverse side
effects including reduced bone mass and increased risk for fracture, reduced lean mass and muscle
strength, mood disturbance and increased fat mass compromising physical functioning,
independence, and quality of life. The purpose of this investigation is to examine the effects of long
term exercise on reversing musculoskeletal-related side effects, and cardiovascular and diabetes
risk factors in men receiving androgen deprivation for their prostate cancer. Specifically, we aim to
investigate the effects of a 12-month exercise program designed to load the musculoskeletal system
and reduce cardiovascular and diabetes disease progression on the following primary endpoints: 1)
bone mineral density; 2) cardiorespiratory function and maximal oxygen capacity; 3) body
composition (lean mass and fat mass); 4) blood pressure and cardiovascular function; 5) lipids and
glycemic control; and 6) quality of life and psychological distress.
Methods/Design: Multi-site randomized controlled trial of 195 men (65 subjects per arm)
undergoing treatment for prostate cancer involving ADT in the cities of Perth and Brisbane in
Australia. Participants will be randomized to (1) resistance/impact loading exercise, (2) resistance/
cardiovascular exercise groups and (3) usual care/delayed exercise. Participants will then undergo
progressive training for 12 months. Measurements for primary and secondary endpoints will take
place at baseline, 6 and 12 months (end of the intervention).
Discussion: The principal outcome of this project will be the determination of the strength of
effect of exercise on the well established musculoskeletal, cardiovascular and insulin metabolism
side effects of androgen deprivation in prostate cancer patients. As this project is much longer term
than previous investigations in the area of exercise and cancer, we will gain knowledge as to the
continuing effects of exercise in this patient population specifically targeting bone density,
cardiovascular function, lean and fat mass, physical function and falls risk as primary study
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endpoints. In terms of advancement of prostate cancer care, we expect dissemination of the
knowledge gained from this project to reduce fracture risk, improve physical and functional ability,
quality of life and ultimately survival rate in this population.
Clinical Trial Registry: A Phase III clinical trial of exercise modalities on treatment side-effects
in men receiving therapy for prostate cancer; ACTRN12609000200280
Background
Worldwide prostate cancer is the second most common
cancer in men representing 19% of cancers among men in
developed countries [1]. With the aging of the population
in developed and developing countries the incidence of
all cancers, which are normally higher in those aged > 65
years, is predicted to substantially rise, particularly for
colon and prostate cancer which are well established
aging-related cancers [2]. Advancing age not only
increases the vulnerability to cancer but also the risk for
other comorbid conditions (e.g. osteoporosis, arthritis
and sarcopenia, cardiovascular disease) [3] that can com-
promise physical function and independent living with
substantial costs to the community ultimately culminat-
ing in death. The introduction of the prostate specific anti-
gen (PSA) blood test into routine clinical practice in
Australia and the USA in the 1990s has led to earlier diag-
nosis of disease [4,5]. Men are often minimally sympto-
matic or, more often, completely asymptomatic and can
be expected to survive substantially longer than their his-
torical counterparts [5,6]. Full characterization of toxicity
of androgen deprivation therapy (ADT) is now seen to be
an important priority for research [6-8].
The use of ADT to reduce testosterone levels in men with
prostate carcinoma is accompanied by a number of
adverse side effects that include reduced bone mass and
increased risk for fracture at multiple sites [9,10], reduced
lean mass and muscle strength [11,12], and increased fat
mass [11] compromising physical functioning, independ-
ence, and quality of life [13]. Existing treatments to allevi-
ate these side effects have been predominantly
pharmacological; however, they are expensive and are not
accompanied by improved physical function. Of equal
concern are recent indications of increased incidence of
coronary and metabolic complications associated with
ADT which raises major problems of therapy toxicity that
are beyond those related to the musculoskeletal system
[14]. As well, ADT is associated with increased emotional
distress [15] and men with advanced prostate cancer expe-
rience higher levels of psychological distress and poorer
quality of life by comparison to men with localized dis-
ease [16,17]. Finally, as there is unquestionable evidence
of the effectiveness of regular exercise in prevention and
management of several chronic diseases including cardio-
vascular disease and diabetes, and even premature death
[18,19], prostate cancer patients on ADT may particularly
benefit from exercise by reducing the risk of co-morbidity
associated with therapy. Preliminary clinical trials by our
team [20-23] and others [24,25] suggest high efficacy of
exercise for these patients. However, the optimal mode of
exercise is yet to be established, the gamut of side-effects
of ADT has not been addressed in a single study, and long
term interventions, which are more clinically relevant and
necessary to assess bone outcomes, have never been
attempted. Of critical importance is patient retention and
compliance with long term exercise prescription. We have
successfully completed several phase 1 and 2 clinical trials
and this paper describes our current phase III trial, where
our aims are to examine the longer terms effects of exer-
cise modality, dosage and patient population implemen-
tation. The penultimate outcome will be clinical
guidelines for the prescription of exercise for the manage-
ment of ADT treatment side effects in all men receiving
such therapy for their prostate cancer resulting in greatly
improved survival, quality of life, function and structure.
The purpose of this investigation is to examine the effects
of long term exercise on reversing musculoskeletal-related
side effects, and cardiovascular and diabetes risk factors in
men receiving ADT for their prostate cancer. Specifically,
we aim to investigate the effects of a 12-month exercise
program designed to load the musculoskeletal system and
reduce cardiovascular and diabetes disease progression on
the following primary endpoints: 1) bone mineral density
(BMD); 2) cardiorespiratory function and maximal oxy-
gen capacity; 3) body composition (lean mass and fat
mass); 4) blood pressure and cardiovascular function; and
5) lipids and glycemic control. Secondary endpoints will
include: 1) physical and neuromuscular function; 2) bal-
ance and risk of falls; and 3) quality of life and psycholog-
ical distress.
This project is unique as it utilizes impact-loading exercise
in addition to resistance exercise as a means to counteract
adverse musculoskeletal treatment related side effects (e.g.
osteoporosis and sarcopenia) of ADT treated patients with
prostate cancer. Further, this study also examines the
effects of cardiorespiratory (aerobic) and resistance (ana-
bolic) exercise as a means to counteract adverse body
composition, cardiovascular and glucose metabolism co-
morbidities related to treatment by ADT for patients with
prostate cancer. Importantly, by comparing clinic versus
home based exercise in one of the groups we will learn
BMC Cancer 2009, 9:210 http://www.biomedcentral.com/1471-2407/9/210
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much about efficacy and feasibility of the home setting for
more practical whole of patient population treatment.
Finally, the extent to which anabolic versus aerobic exer-
cise may ameliorate psychological distress and enhance
quality of life will be assessed. This is the first study to our
knowledge which is specifically designed to address all of
these major side effects of ADT in a long term clinical trial.
Methods/Design
Overview
Subjects will be recruited by invitation of their attending
specialist and from the Prostate Cancer Foundation of
Australia interest groups. Those entering the study will
undertake a series of familiarisation sessions and baseline
measurements prior to randomization to (1) 12 month
program of resistance/impact loading exercise, (2) 12
month program of resistance/cardiovascular exercise and
(3) 6 months usual care (no planned exercise) followed
by 6 months of exercise (delayed). In addition to the twice
weekly training in the clinic setting, all groups will also
undertake twice weekly exercise sessions at home as spec-
ified below. During the course of the study, subjects will
be encouraged to maintain customary activity and dietary
patterns (Figure 1). This protocol has been approved (ID:
08-69 NEWTON) by the University Human Research Eth-
ics Committee.
Subjects
195 men (65 subjects per arm) undergoing treatment for
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(undertaking structured aerobic or resistance training two
or more times per week) within the past 3 months will be
recruited by invitation of their attending specialist in the
Perth and Brisbane areas. All participants will have been
hypogonadal for a period of at least 2 months prior to
commencing the program, and to anticipate remaining so
for the duration of the study. Subjects will be stratified
according to time on ADT (< or = 6 months) and ran-
domly assigned to one of the groups listed above. Individ-
uals with established metastatic bone disease, established
osteoporosis and those taking medications known to
affect bone metabolism, such as bisphosphonates, will be
excluded from participation.
Measurements
Measurements for primary and secondary endpoints will
take place at baseline, 6 and 12 months (end of the inter-
vention).
Primary Study Endpoints
Whole Body, Hip and Spine Bone Mineral Density, and Body 
Composition
BMD (g/cm2) of the hip (total hip) and lumbar spine (L2–
4) regions as well as whole body bone mineral content
(BMC, g) will be assessed by dual-energy X-ray absorpti-
ometry (DXA, Hologic Discovery A, Waltham, MA). The
Instant Vertebral Assessment (IVA) and Quantitative Mor-
phometry (QM) program will be used to determine the
presence or absence of vertebral fractures prior to initia-
tion of the study. In addition, regional and whole body
lean mass (including appendicular skeletal muscle mass)
and fat mass will be derived from the whole body scan.
Measurement of trunk adiposity is an important measure
of chronic disease risk, and will be assessed from trunk fat
mass obtained from the whole body scan and the ratios of
trunk fat to limb fat, and trunk fat to total fat. In addition,
upper and lower limb and trunk muscle tissue will be
measured to evaluate region specific changes in muscle
hypertrophy or atrophy.
Cardiorespiratory Capacity
Maximum oxygen uptake (measure of aerobic capacity)
will be measured by expired air analysis during a staged
walking test on a motorized treadmill. Exercise capacity
(in multiples of resting metabolic rate termed Metabolic
Equivalent of Task – METS) will be determined on the
basis of the speed and grade of the treadmill as well as
direct expired air gas analysis. Electrocardiogram will be
recorded using a 12-lead monitoring system and blood
pressure will be measured each testing minute by sphyg-
momanometer.
Blood Pressure and Arterial Stiffness
A validated oscillometric device (HEM-705CP, Omron
Corporation, Japan) will be used to record brachial BP at
the dominant arm in triplicate. Central (ascending aortic)
BP and indices of arterial stiffness will be determined by
pulse wave analysis using SphygmoCor version 6.1 soft-
ware (AtCor Medical, Sydney, Australia). Radial artery
pressure waveforms will be captured at the right arm by
applanation tonometry using a high fidelity microman-
ometer (SPC-301, Millar Instruments, Houston, Texas,
USA). A generalised transfer function is applied to the
radial artery waveform in order to obtain the pressure
waveform at the ascending aorta. This method has been
validated against invasive techniques for determination of
central BP and the augmentation index (AIx) is a marker
of systemic arterial stiffness.
Blood Markers
Testosterone, prostate specific antigen (PSA), insulin,
lipid profile, glucose, HbA1c, alkaline phosphatase, Pro
collagen Type 1 N-Terminal Propeptide (PINP), and C-
reactive protein (CRP) levels will be measured commer-
cially by an accredited Australian National Association of
Testing Authorities (NATA) laboratory (Pathwest Diag-
nostics, Perth, Western Australia).
Secondary Study Endpoints
Muscle Strength and Endurance
Prior to muscle testing, subjects will be familiarized to all
assessment procedures. In addition, a warm-up consisting
of aerobic activity and stretching will be undertaken.
Dynamic concentric muscle strength for the 6 exercises
undertaken in the program will be measured using the
one repetition maximum (1-RM) method. The 1-RM is
the maximal weight an individual can move through a full
range of motion without change in body position other
than that dictated by the specific exercise motion [26].
Muscle endurance will be assessed using the maximal
number of repetitions performed at 70% of 1-RM for the
chest press and leg press exercises (representing upper and
lower body muscle endurance, respectively) [27].
Physical Function
A battery of tests will be used to assess functional perform-
ance [20,27]. Tests will be performed in triplicate (except
for the 400-m walk which will be performed once) with
sufficient recovery time between trials. The best perform-
ance on each test will be used in the analyses. The tests
will be: 1) Repeated chair rise; 2) Stair climb; 3) 6-meter
backward tandem walk; 4) 6-meter walk, usual and fast
pace; and 5) 400-m walk.
Balance and Risk of Falling
A Neurocom Smart Balancemaster (Neurocom, OR, USA)
will be used to assess static and dynamic balance. This
device measures ground reaction force to track whole
body centre of pressure and a tilting visual field and sup-
port platform to separate the visual, somatosensory and
vestibular balance sense of the patient. During the course
of the intervention, all participants will record any falls
BMC Cancer 2009, 9:210 http://www.biomedcentral.com/1471-2407/9/210
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that take place and submit monthly fall records to the
investigators.
Physical Activity, Quality of Life and Psychological Distress
Self-reported physical activity will be assessed by the lei-
sure score index from the Godin Leisure-Time Exercise
Questionnaire.
Health-related quality of life will be measured using the
EORTC QLQ-C30 and EORTC QLQ-PR25 as well as a
health history questionnaire [13,28]. This validated
instrument is an integrated system to assess quality of life
in cancer patients and has been extensively employed in
clinical trials [29]. The Brief Symptom Inventory-18 (BSI-
18) will be used to assess psychological distress (Anxiety,
Depression and Somatisation) [30].
Exercise Intervention
All three exercise groups: (1) resistance/impact-loading
exercise; (2) resistance/cardiovascular exercise; and (3)
usual care/delayed exercise will train 2 times per week in
an exercise clinic. Weight machines will be used to ensure
participant safety for those in the resistance/impact-load-
ing exercise and the resistance/cardiovascular exercise
groups. The clinic sessions will take approximately 60
minutes (this includes the warm-up and cool-down peri-
ods) and will be conducted in the Exercise Clinics at Edith
Cowan University in Perth and at The University of
Queensland in Brisbane. Sessions will commence with a
10-minute warm-up comprising low-level aerobic activi-
ties such as walking and stationary cycling, as well as
stretching. The resistance training regimen (groups 1 and
2) will include 6 exercises that target the major upper and
lower body muscle groups, which we have used previ-
ously in a number of studies [20,26,27,31-33]. The rest
period between sets will be 1–2 minutes. To ensure the
progressive nature of the training program, subjects will
be encouraged to work past the specific repetition maxi-
mums (RMs) prescribed. The resistance will be increased
by 5–10% increment for the next set/training session if
subjects are able to perform more repetitions than the
RMs specified during a set. Intensity will be manipulated
from 6–12-RM (e.g. the maximal weight that can be lifted
6 to 12 times) using 1–4 sets per exercise.
The impact-loading regimen involves several activities
which we have been previously used in a year-long train-
ing study in postmenopausal women [34]. For the first 12
weeks, 2 rotations will be performed of skipping (30 sec),
bounding over soft hurdles (13–16 cm), and drop jump-
ing (10–15 cm). In the second 12 weeks, hopping on one
leg (10 times) will be added, and 3 rotations of all activi-
ties will be performed. In the third 12-week period, leap-
ing (10 times) will replace skipping, and for the
remainder of the program 4 rotations will be performed of
bounding (19–25 cm), drop jumping (20–25 cm), hop-
ping, and leaping. These activities result in substantial
peak ground reaction forces ranging from 3.4 to 5.2 times
body weight and are deemed to be safe and acceptable by
older people and effective for increasing bone accretion
[34].
All exercise sessions will be conducted in small groups of
up to 10 participants, with participants exercising in pairs
or under direct supervision to ensure correct technique
and minimize the risk for injury. Each session will con-
clude with a 5-minute cool-down period of stretching
activities.
In addition to the clinic training, twice weekly home-
based training will take place. As with the clinic impact-
loading program, the home exercise program will also fol-
low a circuit routine and comprise, in a progressive fash-
ion, 2 to 4 rotations of skipping, hopping, leaping, and
drop jumping.
The usual care/delayed exercise group (group 3) will act as
a control group for the resistance/cardiovascular group in
the initial 6 months and for the resistance/impact loading
intervention group for the full 12 months. Participants in
this group will be provided with a printed booklet with
information about exercise, and in the second 6-month
period cycling (non impact) exercise sessions will be
undertaken twice a week. Further, we will offer partici-
pants in this group a 3-month whole body resistance exer-
cise program following the completion of the second 6-
month period.
The resistance/cardiovascular exercise (group 2) will
undertake the same resistance training regimen as
described above for group (1) that will include 6 exercises
that target the major upper and lower body muscle groups
for the initial 6 months with a follow up home based pro-
gram for the remaining 6 months of the program. In addi-
tion, each clinic session will include 20–30 minutes of
aerobic exercise using various modes such as walking or
jogging on a treadmill, cycling or rowing stationary
ergometer, or exercising on a cross training machine. Tar-
get intensity will be 60%–85% of estimated maximum
heart rate (calculated as 220 – age) with individual heart
rate monitors (Polar Electra Oy, Finland) provided for
each participant. In addition to the clinic training,
patients from group 2 will be encouraged to undertake
home-based training incorporating aerobic activity (e.g.
walking, cycling) with the aim to accumulate at least 150
minutes per week for the duration of the study.
In order to reduce the possibility of boredom or over-
reaching the exercise program will be periodized by
cycling emphasis on intensity and volume. Also, within
BMC Cancer 2009, 9:210 http://www.biomedcentral.com/1471-2407/9/210
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sessions variations of circuit training and intermittent
exercise sessions (intervals of high and low intensity exer-
cise) will be used. The criteria for exercise program design
will be optimal stimulus to the cardiorespiratory and neu-
romuscular systems while maximizing compliance and
retention.
All participants will be asked to maintain customary phys-
ical activity and dietary patterns over the intervention
period, and physical activity and dietary intake will be
assessed at baseline, 6 months and 12 months. During the
course of the study, participants will be required to main-
tain an activity log and record their recreational physical
activities. Dietary intake, at the same time points as for
physical activity, will be assessed using a 4-day dietary
record. Dietary information will be derived using the
FoodWorks software program. A summary of the training
program for the three exercise groups is presented in Fig-
ure 2.
Calculation of Sample Size and Statistical Analysis
Data from our 20-week [20] and 36-week [28] prelimi-
nary studies in prostate cancer patients indicate that the
standard deviation (SD) for change in our primary out-
come of BMD equates to ~4.8%, 3.3%, and 2.5% for the
hip, lumbar spine, and total body, respectively. With ADT,
the annual loss is reported to be 2–8% at the spine and
1.8–6.5% at the hip [35], and based on our 36-week data,
we obtain an annualized loss for the total body of 3.5%.
However, loss in BMD is greatest in the first year of ADT
[36], although continued losses are reported beyond this
time period [36,37]. Consequently, as participants will
have been on ADT for varying time periods and based on
studies to date, we anticipate losses of ~3% and 2.5% at
the clinically relevant fracture sites of the spine and hip,
and 1.5% for the whole body. To be conservative, we
anticipate that our resistance and impact-loading regimen
will result in a modest increase of ~1%, whereas the active
control regimen should have a negligible attenuating
effect on BMD loss. Therefore, we anticipate a difference
between the exercise and control groups of ~3.5% at the
hip, 4.0% at the lumbar spine, and 2.5% for the whole
body, which would be clearly clinically significant and
substantially reduce the risk for fracture. To achieve 90%
power at an alpha level of 0.05 (two-tailed), 40 subjects
per group are required to demonstrate a difference
between groups at each bone site at the end of the 12-
month intervention. Regarding the second main compar-
ison, the resistance training/aerobic group vs. the active
control group for change in maximal exercise capacity as
measured in metabolic equivalents (METS), 48 subjects
per group are required to demonstrate a 0.66 SD differ-
ence between groups at the end of the 6-month interven-
tion period and also potentially at 12-month follow-up
[38,39]. Previous experience with exercise trials that we
have conducted indicates an attrition rate of up to 25%
over the course of the study period. However, to be con-
servative we will account for an attrition rate of up to 35%.
Therefore, to adequately ensure that we have sufficient
subject numbers at the end of the intervention, 65 sub-
jects will be randomized to each of the three groups (N =
195). A sample size of 195 will also provide us with suffi-
cient power to detect differences in our secondary out-
comes.
Data will be analysed using the SPSS statistical software
package. Analyses will include standard descriptive statis-
tics, Student's t tests, correlation and regression, and two-
way (group × time) repeated measures ANOVA to exam-
ine differences between groups over time. All tests will be
two-tailed and an alpha level of 0.05 will be applied as the
criterion for statistical significance.
Discussion
First and foremost, this will be the largest and longest
exercise intervention ever completed with prostate cancer
patients and will produce the strongest efficacy informa-
tion to date. This study is important because it seeks to
examine the longer term outcome of exercise intervention
on the adverse effects of ADT. Whilst benefits of exercise
have been identified in men with ADT, the studies have
only explored short term exposure and assessment. How-
ever, these men may remain on ADT for many months
and years, and the morbidity appears cumulative over this
time. Hence, it is vital to establish the long term benefits
of exercise, as well as the impacts of dose, and type, and
these are the aims of our study. The principal outcome of
this project will be the determination of the strength of
effect of exercise on the well established musculoskeletal,
cardiovascular and insulin metabolism side effects of ADT
in prostate cancer patients. Second, as this project is much
longer term than previous investigations in the area of
exercise and cancer, we will gain knowledge as to the con-
tinuing effects of exercise in this patient population specif-
ically targeting bone density, cardiovascular function,
lean and fat mass, physical function and falls risk. Impor-
tantly, this simple and cost effective intervention strategy
Exercise interventions and timelineFigure 2
Exercise interventions and timeline.
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may provide similar benefits to pharmaceutical interven-
tions (e.g. bisphosphonates) without exposing patients to
additional potential side effects [26,32,40]. Third, exercise
interventions may be an effective means of improving
psychological adjustment and quality of life after cancer
diagnosis and this study will assess this question in an 'at
risk' for distress population. However, the most important
outcome will be clinical guidelines for the design and
implementation of exercise programs for men receiving
ADT for prostate cancer.
In terms of advancement of prostate cancer care, we expect
dissemination of the knowledge gained from this project
to reduce fracture risk, improve physical and functional
ability, quality of life and survival rates in this population.
In particular, we hope to establish that resistance and
impact-loading exercise can have an array of positive
effects for men on ADT that extend beyond the prevention
of osteoporosis. Such effects, apart from enhancing qual-
ity of life, could significantly reduce health care costs.
Although the intervention in this study will be highly
supervised, it lends itself to being performed at a lower
level of supervision in practice, and part of the program is
already designed to be undertaken in the home setting.
This phase of the study will increase our understanding of
exercise undertaken by men of their own volition, an
important outcome for successful implementation of
exercise for the entire patient population.
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